carboplatin + cisplatin + nab-paclitaxel + pembrolizumab + pemetrexed

This is a combination therapy consisting of multiple anticancer agents used in the treatment of non-small cell lung cancer (NSCLC). The combination includes: - Platinum-based chemotherapy agents (carboplatin and cisplatin) - Nab-paclitaxel (albumin-bound paclitaxel) - Pembrolizumab (an immune checkpoint inhibitor) - Pemetrexed (an antifolate antimetabolite) Different components of this combination have been studied in various clinical trials, though not necessarily all five agents together. Carboplatin or cisplatin are typically used as alternative platinum agents rather than together. These combinations have shown efficacy in treating advanced NSCLC with manageable toxicity profiles.